Skip to main content
SpringerLink
Log in

Mimics of Autoimmune Hepatitis: Drug Induced and Immune Mediated Liver Disease

  • Chapter
  • First Online:
Autoimmune Hepatitis

Part of the book series: Clinical Gastroenterology ((CG))

  • 1094 Accesses

Abstract

The liver is the target of numerous acute and chronic inflammatory processes. Major causes for pathogenic processes are hepatotropic viruses, toxicity of drugs and their metabolites, autoimmune processes, or genetic defects. Thus, the pathogenesis of autoimmune liver diseases may extend well beyond AIH and primary biliary cirrhosis. Serological markers of autoimmunity may be detected with alcoholic and non-alcoholic fatty liver disease, acute and chronic viral hepatitis, and drug-induced hepatitis. It is however important to distinguish between autoimmune reactions and autoimmune diseases. The pathogenetic role of most, if not all, autoantibodies is still unclear and it is not known whether autoantibodies that are observed in primarily non-autoimmune liver disease contribute to tissue damage. In most liver diseases associated with serological markers of AIH, autoantibodies against phase I and phase II drug metabolizing enzymes may also be detected. Autoimmune reactions against members of the families of cytochromes P450 (P450) and UDP – glucuronosyltransferases (UGT) will also be discussed.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Czaja A, Carpenter HA. Validation of scoring system for diagnosis of autoimmune hepatitis. Dig Dis Sci. 1996;41:305–14.

    Article  PubMed  CAS  Google Scholar 

  2. Loria P, Lonardo A, Leonardi F, Fontana C, Carulli L, Verrone AM, et al. Non-organ-specific autoantibodies in nonalcoholic fatty liver disease: prevalence and correlates. Dig Dis Sci. 2003;48:2173–81.

    Article  PubMed  Google Scholar 

  3. Adams LA, Lindor KD, Angulo P. The prevalence of autoantibodies and autoimmune hepatitis in patients with nonalcoholic Fatty liver disease. Am J Gastroenterol. 2004;99:1316–20.

    Article  PubMed  CAS  Google Scholar 

  4. Mackie FD, Peakman M, Ma Y, Sallie R, Smith H, Davis ET, et al. Primary and secondary liver/kidney microsomal response following infection with hepatitis C virus. Gastroenterology. 1994;106:1672–5.

    PubMed  CAS  Google Scholar 

  5. Cassani F, Muratori L, Manotti P, Lenzi M, Fusconi M, Ballardini G, et al. Serum autoantibodies and the diagnosis of type-1 autoimmune hepatitis in Italy: a reappraisal at the light of hepatitis C virus infection. Gut. 1992;33:1260–3.

    Article  PubMed  CAS  Google Scholar 

  6. Abuaf N, Lunel F, Giral P, Borotto E, Laperche S, Poupon R, et al. Non-organ specific autoantibodies associated with chronic C virus hepatitis. J Hepatol. 1993;18:359–64.

    Article  PubMed  CAS  Google Scholar 

  7. Czaja AJ. Autoimmune hepatitis and viral infection. Gastroenterol Clin North Am. 1994;23:547–66.

    PubMed  CAS  Google Scholar 

  8. Pawlotsky JM, Roudot-Thoraval F, Simmonds P, Mellor J, Ben Yahia MB, Andre C, et al. Extrahepatic immunologic manifestations in chronic hepatitis C and hepatitis C virus serotypes. Ann Intern Med. 1995;122:169–73.

    PubMed  CAS  Google Scholar 

  9. Clifford BD, Donahue D, Smith S, Cable E, Luttig B, Manns MP, et al. High prevalence of serological markers of autoimmunity in patients with chronic hepatitis C. Hepatology. 1995;231:613–9.

    Google Scholar 

  10. Czaja AJ, Carpenter HA, Santrach PJ, Moore SB. Immunologic features and HLA associations in chronic viral hepatitis. Gastroenterology. 1995;108:157–64.

    Article  PubMed  CAS  Google Scholar 

  11. Czaja AJ, Carpenter HA. Histological findings in chronic hepatitis C with autoimmune features. Hepatology. 1997;26:459–66.

    Article  PubMed  CAS  Google Scholar 

  12. Czaja AJ. Extrahepatic immunologic features of chronic viral hepatitis. Dig Dis. 1997;15:125–44.

    Article  PubMed  CAS  Google Scholar 

  13. Maddrey WC, Boitnott JK. Drug-induced chronic liver disease. Gastroenterology. 1977;72:1348–53.

    PubMed  CAS  Google Scholar 

  14. Seeff LB. Drug-induced chronic liver disease, with emphasis on chronic active hepatitis. Semin Liver Dis. 1981;1:104–15.

    Article  PubMed  CAS  Google Scholar 

  15. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther. 1994;270:414–23.

    PubMed  CAS  Google Scholar 

  16. Strassburg CP, Manns MP. Autoantibodies and autoantigens in autoimmune hepatitis. Semin Liver Dis. 2002;22:339–52.

    Article  PubMed  CAS  Google Scholar 

  17. Rizzetto M, Swana G, Doniach D. Microsomal antibodies in active chronic hepatitis and other disorders. Clin Exp Immunol. 1973;15:331–44.

    PubMed  CAS  Google Scholar 

  18. Homberg JC, Abuaf N, Bernard ON, Islam S, Alvarez F, Khalil SH, et al. Chronic active hepatitis associated with anti liver/kidney microsome type 1: a second type of “autoimmune” hepatitis. Hepatology. 1987;7:1333–9.

    Article  PubMed  CAS  Google Scholar 

  19. Manns MP, Johnson EF, Griffin KJ, Tan EM, Sullivan KF. Major antigen of liver kidney microsomal antibodies in idiopathic autoimmune hepatitis is cytochrome P450db1. J Clin Invest. 1989;83:1066–72.

    Article  PubMed  CAS  Google Scholar 

  20. Guenguen M, Meunier-Rotival M, Bernard O, Alvarez F. Anti-liver-kidney microsome antibody recognizes a cytochrome P450 from the IID subfamily. J Exp Med. 1988;168:801.

    Article  Google Scholar 

  21. Manns MP, Griffin KJ, Sullivan KF, Johnson EF. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest. 1991;88:1370–8.

    Article  PubMed  CAS  Google Scholar 

  22. Yamamoto AM, Cresteil D, Boniface O, Clerc FF, Alvarez F. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol. 1993;23:1105–11.

    Article  PubMed  CAS  Google Scholar 

  23. Klein R, Zanger UM, Berg T, Hopf U, Berg PA. Overlapping but distinct specificities of anti-liver-kidney microsome antibodies in autoimmune hepatitis type II and hepatitis C revealed by recombinant native CYP2D6 and novel peptide epitopes. Clin Exp Immunol. 1999;118:290–7.

    Article  PubMed  CAS  Google Scholar 

  24. Kerkar N, Choudhuri K, Ma Y, Mahmoud A, Bogdanos DP, Muratori L, et al. Cytochrome P4502D6(193–212): a new immunodominant epitope and target of virus/self cross-reactivity in liver kidney microsomal autoantibody type 1-positive liver disease. J Immunol. 2003;170:1481–9.

    PubMed  CAS  Google Scholar 

  25. Sugimura T, Obermayer-Straub P, Kayser A, Braun S, Loges S, Alex B, et al. A major CYP2D6 auto epitope in autoimmune hepatitis type 2 and chronic hepatitis C is a three-dimensional structure homologous to other cytochrome P450 autoantigens. Autoimmunity. 2002;35:501–13.

    Article  PubMed  CAS  Google Scholar 

  26. Manns M, Zanger U, Gerken G, Sullivan KF, Meyer zum Büschenfelde KH, Meyer UA, et al. Patients with type II autoimmune hepatitis express functionally intact cytochrome P450 db1 that is inhibited by LKM1 autoantibodies in vitro but not in vivo. Hepatology. 1990;12:127–32.

    Article  PubMed  CAS  Google Scholar 

  27. Loeper J, Descatoire V, Maurice M, Beaune P, Belghiti J, Houssin D, et al. Cytochromes P-450 in human hepatocyte plasma membrane: recognition by several autoantibodies. Gastroenterology. 1993;104:203–16.

    PubMed  CAS  Google Scholar 

  28. Muratori L, Parola M, Ripalti A, Robino G, Muratori P, Bellomo G, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane [see comments]. Gut. 2000;46:553–61.

    Article  PubMed  CAS  Google Scholar 

  29. Zanger UM, Hauri HP, Loeper J, Homberg JC, Meyer UA. Antibodies against human cytochrome P-450db1 in autoimmune hepatitis type 2. Proc Natl Acad Sci USA. 1988;85:8256–60.

    Article  PubMed  CAS  Google Scholar 

  30. Rowland P, Blaney FE, Smyth MG, Jones JJ, Leydon VR, Oxbrow AK, et al. Crystal structure of human cytochrome P450 2D6. J Biol Chem. 2006;281:7614–22.

    Article  PubMed  CAS  Google Scholar 

  31. Ahonen P, Myllarniemi S, Sipila I, Perheentupa J. Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. N Engl J Med. 1990;322:1829–36.

    Article  PubMed  CAS  Google Scholar 

  32. Nagamine K, Peterson P, Scott HS, Kudoh J, Minoshima S, Heino M, et al. Positional cloning of the APECED gene. Nat Genet. 1997;17:393–8.

    Article  PubMed  CAS  Google Scholar 

  33. Vogel A, Strassburg CP, Obermayer-Straub P, Brabant G, Manns MP. The genetic background of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy and its autoimmune disease components. J Mol Med. 2002;80:201–11.

    Article  PubMed  CAS  Google Scholar 

  34. Podkrajsek KT, Bratanic N, Krzisnik C, Battelino T. AIRE-1 mRNA analysis in a novel intronic mutation and two additional novel AIRE gene mutations in a cohort of APECED patients. J Clin Endocrinol Metab. 2005;90:4930–5.

    Article  PubMed  CAS  Google Scholar 

  35. Vogel A, Liermann H, Harms A, Strassburg CP, Manns MP, Obermayer-Straub P. Autoimmune regulator AIRE: evidence for genetic differences between autoimmune hepatitis and hepatitis as part of the autoimmune polyglandular syndrome type 1. Hepatology. 2001;33:1047–52.

    Article  PubMed  CAS  Google Scholar 

  36. Djilali-Saiah I, Renous R, Caillat-Zucman S, Debray D, Alvarez F. Linkage disequilibrium between HLA class II region and autoimmune hepatitis in pediatric patients. J Hepatol. 2004;40:904–9.

    Article  PubMed  CAS  Google Scholar 

  37. Clemente MG, Obermayer-Straub P, Meloni A, Strassburg CP, Arangino V, Tukey RH, et al. Cytochrome P450 1A2 is a hepatic autoantigen in autoimmune polyglandular syndrome type 1. J Clin Endocrinol Metab. 1997;82:1353–61.

    Article  PubMed  CAS  Google Scholar 

  38. Clemente MG, Meloni A, Obermayer-Straub P, Frau F, Manns MP, De Virgiliis S. Two cytochromes P450 are major hepatocellular autoantigens in autoimmune polyglandular syndrome type 1. Gastroenterology. 1998;114:324–8.

    Article  PubMed  CAS  Google Scholar 

  39. Obermayer-Straub P, Perheentupa J, Braun S, Kayser A, Barut A, Loges S, et al. Hepatic autoantigens in patients with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy. Gastroenterology. 2001;121:668–77.

    Article  PubMed  CAS  Google Scholar 

  40. Soderbergh A, Myhre AG, Ekwall O, Gebre-Medhin G, Hedstrand H, Landgren E, et al. Prevalence and clinical associations of 10 defined autoantibodies in autoimmune polyendocrine syndrome type I. J Clin Endocrinol Metab. 2004;89:557–62.

    Article  PubMed  CAS  Google Scholar 

  41. Peterson P, Krohn JE. Mapping of B cell epitopes on steroid 17a-hydroxylase, an autoantigen in autoimmune polyglandular syndrome type I. Clin Exp Immunol. 1994;989:104–10.

    Google Scholar 

  42. Uibo R, Aavik E, Peterson P, Perheentupa J, Aranko S, Pelkonen R, et al. Autoantibodies to cytochrome P450 enzymes P450scc, P450c17, and P450c21 in autoimmune polyglandular disease types I and II and in isolated Addison’s disease. J Clin Endocrinol Metabol. 1994;78:323–8.

    Article  CAS  Google Scholar 

  43. Winqvist O, Gustafsson J, Rorsman F, Karlsson FA, Kampe O. Two different cytochrome P450 enzymes are the adrenal antigens in autoimmune polyendocrine syndrome type I and Addison’s disease. J Clin Invest. 1993;92:2377–85.

    Article  PubMed  CAS  Google Scholar 

  44. Dalekos GN, Obermayer-Straub P, Bartels M, Maeda T, Kayser A, Braun S, et al. Cytochrome P450 2A6: a new hepatic autoantigen in patients with chronic hepatitis C virus infection. J Hepatol. 2003;39:800–6.

    Article  PubMed  CAS  Google Scholar 

  45. Muratori L, Lenzi M, Cataleta M, Giostra F, Ballardini G. Interferon therapy in liver/kidney microsomal antibody type 1-positive patients with chronic hepatitis C. J Hepatology. 1994;21:199–203.

    Article  CAS  Google Scholar 

  46. Dalekos GN, Wedemeyer H, Obermayer-Straub P, Kayser A, Barut A, Frank H, et al. Epitope mapping of cytochrome P4502D6 autoantigen in patients with chronic hepatitis C during alpha-interferon treatment. J Hepatol. 1999;30:366–75.

    Article  PubMed  CAS  Google Scholar 

  47. Ferri S, Muratori L, Quarneti C, Muratori P, Menichella R, Pappas G, et al. Clinical features and effect of antiviral therapy on anti-liver/kidney microsomal antibody type 1 positive chronic hepatitis C. J Hepatol. 2009;50:1093–101.

    Article  PubMed  CAS  Google Scholar 

  48. Zimmerman HJ, Lewis JH, Ishak KG, Maddrey WC. Ticrynafen-associated hepatic injury: analysis of 340 cases. Hepatology. 1984;4:315–23.

    Article  PubMed  CAS  Google Scholar 

  49. Bernuau J, Mallet L, Benhamou JP. Hepatotoxicity due to tienilic acid. Gastroenterol Clin Biol. 1981;5:692–3.

    PubMed  CAS  Google Scholar 

  50. Homberg JC, Andre C, Abuaf N. A new anti-liver-kidney microsome antibody (anti-LKM2) in tienilic acid-induced hepatitis. Clin Exp Immunol. 1984;55:561–70.

    PubMed  CAS  Google Scholar 

  51. Robin MA, Maratrat M, Le Roy M, Le Breton FP, Bonierbale E, Dansette P, et al. Antigenic targets in tienilic acid hepatitis. Both cytochrome P450 2 C11 and 2 C11-tienilic acid adducts are transported to the plasma membrane of rat hepatocytes and recognized by human sera. J Clin Invest. 1996;98:1471–80.

    Article  PubMed  CAS  Google Scholar 

  52. Beaune P, Dansette PM, Mansuy D, Kiffel L, Finck M, Amar C, et al. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug. Proc Natl Acad Sci USA. 1987;84:551–5.

    Article  PubMed  CAS  Google Scholar 

  53. Bourdi M, Larrey D, Nataf J, Bernuau J, Pessayre D, Iwasaki M, et al. Anti-liver endoplasmic reticulum autoantibodies are directed against human cytochrome P-450IA2. A specific marker of dihydralazine-induced hepatitis. J Clin Invest. 1990;85:1967–73.

    Article  PubMed  CAS  Google Scholar 

  54. Manns MP, Griffin KJ, Quattrochi LC, Sacher M, Thaler H, Tukey RH, et al. Identification of cytochrome P450IA2 as a human autoantigen. Arch Biochem Biophys. 1990;280:229–32.

    Article  PubMed  CAS  Google Scholar 

  55. Siegmund W, Franke G, Biebler KE, Donner I, Kallwellis R, Kairies M, et al. The influence of the acetylator phenotype for the clinical use of dihydralazine. Int J Clin Pharmacol Ther Toxicol. 1985;23 Suppl 1:S74–8.

    PubMed  Google Scholar 

  56. Kharasch ED, Hankins D, Mautz D, Thummel KE. Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet. 1996;347:1367–71.

    Article  PubMed  CAS  Google Scholar 

  57. Eliasson E, Kenna JG. Cytochrome P450 2E1 is a cell surface autoantigen in halothane hepatitis. Mol Pharmacol. 1996;50:573–82.

    PubMed  CAS  Google Scholar 

  58. Leeder JS, Riley RJ, Cook VA, Spielberg SP. Human anti-cytochrome P450 antibodies in aromatic anticonvulsant-induced hypersensitivity reactions. J Pharmacol Exp Ther. 1992;263:360–7.

    PubMed  CAS  Google Scholar 

  59. Shear NH, Spielberg SP. Anticonvulsant hypersensitivity syndrome: in vitro assessment of risk. J Clin Invest. 1988;82:1826–32.

    Article  PubMed  CAS  Google Scholar 

  60. Riley RJ, Smith G, Wolf R, Cook VA, Leeder JS. Human anti-endoplasmatic reticulum autoantibodies produced in aromatic anticonvulsant hypersensitivity reactions recognise rodent CYP3a proteins and similarily regulated human P450 enzyme(s). Biochem Biophys Res Comm. 1993;191:32–40.

    Article  PubMed  CAS  Google Scholar 

  61. Albano E, Vidali M. Immune mechanisms in alcoholic liver disease. Genes Nutr. 2009;5:141–7.

    Article  Google Scholar 

  62. Chedid A, Chadalawada KR, Morgan TR, Moritz TE, Mendenhall CL, Hammond JB, et al. Phospholipid antibodies in alcoholic liver disease. Hepatology. 1994;20:1465–71.

    Article  PubMed  CAS  Google Scholar 

  63. Rolla R, Vay D, Mottaran E, Parodi M, Vidali M, Sartori M, et al. Antiphospholipid antibodies associated with alcoholic liver disease specifically recognise oxidised phospholipids. Gut. 2001;49:852–9.

    Article  PubMed  CAS  Google Scholar 

  64. Clot P, Bellomo G, Tabone M, Arico S, Albano E. Detection of antibodies against proteins modified by hydroxyethyl free radicals in patients with alcoholic cirrhosis. Gastroenterology. 1995;108:201–7.

    Article  PubMed  CAS  Google Scholar 

  65. Clot P, Albano E, Eliasson E, Tabone M, Sarino A, Israel Y, et al. Cytochrome P450 2E1 hydroxyethyl radical adducts as the major antigen in autoantibody formation among alcoholics. Gastroenterology. 1996;111:206–16.

    Article  PubMed  CAS  Google Scholar 

  66. Israel Y, Hurwitz E, Niemela O, Arnon R. Monoclonal and polyclonal antibodies against acetaldehyde-containing epitopes in acetaldehyde-protein adducts. Proc Natl Acad Sci USA. 1986;83:7923–7.

    Article  PubMed  CAS  Google Scholar 

  67. Albano E, Tomasi A, Goria-Gatti L, Persson JO, Terelius Y, Ingelman-Sundberg M, et al. Role of ethanol-inducible cytochrome P450 (P450IIE1) in catalysing the free radical activation of aliphatic alcohols. Biochem Pharmacol. 1991;41:1895–902.

    Article  PubMed  CAS  Google Scholar 

  68. Lytton SD, Helander A, Zhang-Gouillon ZQ, Stokkeland K, Bordone R, Arico S, et al. Autoantibodies against cytochromes P-4502E1 and P-4503A in alcoholics. Mol Pharmacol. 1999;55:223–33.

    PubMed  CAS  Google Scholar 

  69. Wu D, Cederbaum AI. Presence of functionally active cytochrome P-450IIE1 in the plasma membrane of rat hepatocytes. Hepatology. 1992;15:515–24.

    Article  PubMed  CAS  Google Scholar 

  70. Griem P, Wulferink M, Sachs B, Gonzalez JB, Gleichmann E. Allergic and autoimmune reactions to xenobiotics: how do they arise? Immunol Today. 1998;19:133–41.

    Article  PubMed  CAS  Google Scholar 

  71. Van Pelt FN, Straub P, Manns MP. Molecular basis of drug-induced immunological liver injury. Semin Liver Dis. 1995;15:283–300.

    Article  PubMed  Google Scholar 

  72. Manns MP, Obermayer-Straub P. Cytochromes P450 and UDP-glucuronosyltransferases: model autoantigens to study drug-induced, virus-induced and autoimmune liver disease. Hepatology. 1997;26:1054–66.

    Article  PubMed  CAS  Google Scholar 

  73. Wen L, Ma Y, Bogdanos DP, Wong FS, Demaine A, Mieli-Vergani G, et al. Pediatric autoimmune liver diseases: the molecular basis of humoral and cellular immunity. Curr Mol Med. 2001;1:379–89.

    Article  PubMed  CAS  Google Scholar 

  74. Ma Y, Bogdanos DP, Hussain MJ, Underhill J, Bansal S, Longhi MS, et al. Polyclonal T-cell responses to cytochrome P450IID6 are associated with disease activity in autoimmune hepatitis type 2. Gastroenterology. 2006;130:868–82.

    Article  PubMed  CAS  Google Scholar 

  75. Kammer AR, Van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KMC, Reichen J, et al. Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J Exp Med. 1999;190:169–76.

    Article  PubMed  CAS  Google Scholar 

  76. Choudhuri K, Gregorio GV, Mieli-Vergani G, Vergani D. Immunological cross-reactivity to multiple autoantigens in patients with liver kidney microsomal type 1 autoimmune hepatitis. Hepatology. 1998;28:1177–81.

    Article  PubMed  CAS  Google Scholar 

  77. Holdener M, Hintermann E, Bayer M, Rhode A, Rodrigo E, Hintereder G, et al. Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. J Exp Med. 2008;205:1409–22.

    Article  PubMed  CAS  Google Scholar 

  78. Christen U, Hintermann E, Holdener M, von Herrath MG. Viral triggers for autoimmunity: Is the ‘glass of molecular mimicry’ half full or half empty? J Autoimmun. 2009;34:38–44.

    Article  PubMed  CAS  Google Scholar 

  79. Senaldi G, Portmann B, Mowat AP, Mieli-Vergani G, Vergani D. Immunohistochemical features of the portal tract mononuclear cell infiltrate in chronic aggressive hepatitis. Arch Dis Child. 1992;67:1447–53.

    Article  PubMed  CAS  Google Scholar 

  80. Lohr H, Manns M, Kyriatsoulis A, Lohse AW, Trautwein C, Meyer zum Buschenfelde KH, et al. Clonal analysis of liver-infiltrating T cells in patients with LKM-1 antibody-positive autoimmune chronic active hepatitis. Clin Exp Immunol. 1991;84:297–302.

    Article  PubMed  CAS  Google Scholar 

  81. Lohr HF, Schlaak JF, Lohse AW, Bocher WO, Arenz M, Gerken G, et al. Autoreactive CD4+ LKM-specific and anticlonotypic T-cell responses in LKM-1 antibody-positive autoimmune hepatitis. Hepatology. 1996;24:1416–21.

    Article  PubMed  CAS  Google Scholar 

  82. Longhi MS, Hussain MJ, Bogdanos DP, Quaglia A, Mieli-Vergani G, Ma Y, et al. Cytochrome P450IID6-specific CD8 T cell immune responses mirror disease activity in autoimmune hepatitis type 2. Hepatology. 2007;46:472–84.

    Article  PubMed  CAS  Google Scholar 

  83. Nouri-Aria KT, Donaldson PT, Hegarty JE, Eddleston AL, Williams R. HLA A1-B8-DR3 and suppressor cell function in first-degree relatives of patients with autoimmune chronic active hepatitis. J Hepatol. 1985;1:235–41.

    Article  PubMed  CAS  Google Scholar 

  84. Shevach EM, Piccirillo CA, Thornton AM, McHugh RS. Control of T cell activation by CD4  +  CD25+ suppressor T cells. Novartis Found Symp. 2003;252:24–36. discussion 36–44, 106–114.

    Article  PubMed  CAS  Google Scholar 

  85. Longhi MS, Hussain MJ, Mitry RR, Arora SK, Mieli-Vergani G, Vergani D, et al. Functional study of CD4  +  CD25+ regulatory T cells in health and autoimmune hepatitis. J Immunol. 2006;176:4484–91.

    PubMed  CAS  Google Scholar 

  86. Longhi MS, Ma Y, Mitry RR, Bogdanos DP, Heneghan M, Cheeseman P, et al. Effect of CD4+ CD25+ regulatory T-cells on CD8 T-cell function in patients with autoimmune hepatitis. J Autoimmun. 2005;25:63–71.

    Article  PubMed  CAS  Google Scholar 

  87. Bock KW. Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects. Biochem Pharmacol. 2003;66:691–6.

    Article  PubMed  CAS  Google Scholar 

  88. Miners JO, Smith PA, Sorich MJ, McKinnon RA, Mackenzie PI. Predicting human drug glucuronidation parameters: application of in vitro and in silico modeling approaches. Annu Rev Pharmacol Toxicol. 2004;44:1–25.

    Article  PubMed  CAS  Google Scholar 

  89. Mackenzie PI, Bock KW, Burchell B, Guillemette C, Ikushiro S, Iyanagi T, et al. Nomenclature update for the mammalian UDP glycosyltransferase (UGT) gene superfamily. Pharmacogenet Genomics. 2005;15:677–85.

    Article  PubMed  CAS  Google Scholar 

  90. Crivelli O, Lavarini C, Chiaberge E, Amoroso A, Farci P, Negro F, et al. Microsomal autoantibodies in chronic infection with HBsAg associated delta (delta) agent. Clin Exp Immunol. 1983;54:232–8.

    PubMed  CAS  Google Scholar 

  91. Philipp T, Durazzo M, Trautwein C, Alex B, Straub P, Lamb JG, et al. Recognition of uridine diphosphate glucuronosyl transferases by LKM-3 antibodies in chronic hepatitis D. Lancet. 1994;344:578–81.

    Article  PubMed  CAS  Google Scholar 

  92. Tukey RH, Strassburg CP. Genetic multiplicity of the human UDP-glucuronosyltransferases and regulation in the gastrointestinal tract. Mol Pharmacol. 2001;59:405–14.

    PubMed  CAS  Google Scholar 

  93. Tukey RH, Strassburg CP. Human UDP-glucuronosyltransferases: metabolism, expression, and disease. Annu Rev Pharmacol Toxicol. 2000;40:581–616.

    Article  PubMed  CAS  Google Scholar 

  94. Durazzo M, Philipp T, Van Pelt FN, Luttig B, Borghesio E, Michel G, et al. Heterogeneity of liver-kidney microsomal autoantibodies in chronic hepatitis C and D virus infection. Gastroenterology. 1995;108:455–62.

    Article  PubMed  CAS  Google Scholar 

  95. Strassburg CP, Obermayer-Straub P, Alex B, Durazzo M, Rizzetto M, Tukey RH, et al. Autoantibodies against glucuronosyltransferases differ between viral hepatitis and autoimmune hepatitis. Gastroenterology. 1996;111:1576–86.

    Article  PubMed  CAS  Google Scholar 

  96. Obermayer-Straub P, Strassburg C, Clemente M-G, Philipp T, Tukey RH, Manns MP. Recognition of three different epitopes on UDP-glucuronosyltransferases by LKM-3 antibodies in patients with autoimmune hepatitis and hepatitis D. Gut. 1995;37(2):A100.

    Google Scholar 

  97. Gough A, Chapman S, Wagstaff K, Emery P, Elias E. Minocycline induced autoimmune hepatitis and systemic lupus erythematosus-like syndrome. BMJ. 1996;312:169–72.

    Article  PubMed  CAS  Google Scholar 

  98. Crosson J, Stillman MT. Minocycline-related lupus erythematosus with associated liver disease. J Am Acad Dermatol. 1997;36:867–8.

    Article  PubMed  CAS  Google Scholar 

  99. Herzog D, Hajoui O, Russo P, Alvarez F. Study of immune reactivity of minocycline-induced chronic active hepatitis. Dig Dis Sci. 1997;42:1100–3.

    Article  PubMed  CAS  Google Scholar 

  100. Helfgott SM, Sandberg-Cook J, Zakim D, Nestler J. Diclofenac-associated hepatotoxicity. JAMA. 1990;264:2660–2.

    Article  PubMed  CAS  Google Scholar 

  101. Scully LJ, Clarke D, Barr RJ. Diclofenac induced hepatitis. 3 cases with features of autoimmune chronic active hepatitis. Dig Dis Sci. 1993;38:744–51.

    Article  PubMed  CAS  Google Scholar 

  102. Geramno VPDA, Baccano G, Natale E, Onetto Muda A, Priori R, Valesini G. Autoimmune hepatitis associated with infliximab in a patient with psoriatic arthritis. Ann Rheum Dis. 2005;64:1519–20.

    Article  Google Scholar 

  103. Fedotin MS, Lefer LG. Liver disease caused by propylthiouracil. Arch Intern Med. 1975;135:319–21.

    Article  PubMed  CAS  Google Scholar 

  104. Heyningen CV. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe. Ann Clin Biochem. 2005;42:402–4.

    Article  PubMed  Google Scholar 

  105. Sharp JR, Ishak KG, Zimmerman HJ. Chronic active hepatitis and severe hepatic necrosis associated with nitrofurantoin. Ann Intern Med. 1980;92:14–9.

    PubMed  CAS  Google Scholar 

  106. Maddrey WC, Boitnott JK. Severe hepatitis from methyldopa. Gastroenterology. 1975;68:351–60.

    Google Scholar 

  107. Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology. 1975;69:289–302.

    PubMed  CAS  Google Scholar 

  108. Manns MP, Vogel A. Autoimmune hepatitis, from mechanisms to therapy. Hepatology. 2006;43:S132–44.

    Article  PubMed  CAS  Google Scholar 

  109. Vento S, Cainelli F, Renzini C, Conica E. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet. 1997;350:1298–9.

    Article  PubMed  CAS  Google Scholar 

  110. Vento S, Garofano T, Di Perri G, Dolci L, Conica E, Basetti D. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet. 1991;337:1183–7.

    Article  PubMed  CAS  Google Scholar 

  111. Vento S, Cainelli F, Ferraro T, Conica E. Autoimmune hepatitis type 1 after measles. Am J Gastroenterol. 1996;91:2618–20.

    PubMed  CAS  Google Scholar 

  112. Vento S, Guella L, Mirandola F, Cainelli F, Di Perri G, Ferraro T, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet. 1995;346:608–9.

    Article  PubMed  CAS  Google Scholar 

  113. Schmitt K, Deutsch J, Tulzer G, Meindi R, Aberle S. Autoimmune hepatitis and adrenal insufficiency in an infant with human herpesvirus-6 infection. Lancet. 1996;348:966.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany

    Arndt Vogel & Michael P. Manns

Authors
  1. Arndt Vogel
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michael P. Manns
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Michael P. Manns .

Editor information

Editors and Affiliations

  1. Toronto Western Hospital Liver Centre, Department of Medicine, University of Toronto, Bathhurst St. 399, Toronto, M5T 2S8, Ontario, Canada

    Gideon M. Hirschfield

  2. Toronto Western Hospital Liver Centre, University of Toronto, Bathhurst St. 399, Toronto, M5T 2S8, Ontario, Canada

    E. Jenny Heathcote

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Vogel, A., Manns, M.P. (2012). Mimics of Autoimmune Hepatitis: Drug Induced and Immune Mediated Liver Disease. In: Hirschfield, G., Heathcote, E. (eds) Autoimmune Hepatitis. Clinical Gastroenterology. Springer, New York, NY. https://doi.org/10.1007/978-1-60761-569-9_5

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-569-9_5

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-60761-568-2

  • Online ISBN: 978-1-60761-569-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation